Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes
- 1Haemostasis and Thrombosis Unit Cruces University Hospital Bizkaia Basque Country Spain
- 2Molecular Biology Laboratory Cruces University Hospital Bizkaia Basque Country Spain
- 3Department of Haematology and Haemotherapy Cruces University Hospital Bizkaia Basque Country Spain
Abstract
Prophylaxis with a plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII) 1:1 concentrate (wilate) is effective in the treatment of severe type 3 von Willebrand disease (VWD). However, uptake of prophylaxis with factor concentrates remains limited due in part to the treatment burden and historical concerns over blood product safety. We describe clinical cases of two adult twin brothers with severe type 3 VWD and a history of hepatitis C acquired from childhood plasma-derived products, who initiated once-weekly pdVWF/FVIII 1:1 concentrate prophylaxis after years of on-demand therapy. Both patients completed 12 months of prophylaxis, which led to a marked improvement in bleeding control and daily functioning, and a decrease in treatment burden compared with on-demand treatment. Their experiences highlight the significant enhancement in quality of life achieved through the adoption of regular prophylaxis. Overcoming long-standing concerns about product safety allowed them to embrace preventive care and realize its benefits in managing their severe VWD.
Related
- Empirical Antibiotic Initiation for Suspected Early-Onset Neonatal Infection in the Setting of Maternal GBS Screening and Intrapartum Antibiotic Prophylaxis: A Single-Center Retrospective Cohort Study
- Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
- PO081 | FROM VON WILLEBRAND DISEASE TO MILD HEMOPHILIA A AND BACK: THREE ILLUSTRATIVE CASES HIGHLIGHTING THE ROLE OF GENETIC TESTING IN IMPROVING DIAGNOSTIC ACCURACY
- Improving surgical antibiotic prophylaxis in obstetric and gynaecological surgery: a prospective two-cycle quality-improvement clinical audit in a North African tertiary hospital.
- Mouse models to study von Willebrand factor in thrombosis: a scoping review
BibTeX
@article{sierra2026late,
title = {{Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes}},
author = {Cristina Sierra and Maria José Ojinaga and Lucia Insunza and Gorka Pinedo and Javier Arzuaga and Juan Carlos García-Ruiz},
journal = {TH Open: Companion Journal to Thrombosis and Haemostasis},
year = {2026},
month = nov,
doi = {10.1055/a-2990-4466},
url = {https://doi.org/10.1055/a-2990-4466},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes
AU - Cristina Sierra
AU - Maria José Ojinaga
AU - Lucia Insunza
AU - Gorka Pinedo
AU - Javier Arzuaga
AU - Juan Carlos García-Ruiz
PY - 2026
DA - 2026/11/05
JO - TH Open: Companion Journal to Thrombosis and Haemostasis
DO - 10.1055/a-2990-4466
UR - https://doi.org/10.1055/a-2990-4466
AB - Prophylaxis with a plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII) 1:1 concentrate (wilate) is effective in the treatment of severe type 3 von Willebrand disease (VWD). However, uptake of prophylaxis with factor concentrates remains limited due in part to the treatment burden and historical concerns over blood product safety. We describe clinical cases of two adult twin brothers with severe type 3 VWD and a history of hepatitis C acquired from childhood plasma-derived products, who initiated once-weekly pdVWF/FVIII 1:1 concentrate prophylaxis after years of on-demand therapy. Both patients completed 12 months of prophylaxis, which led to a marked improvement in bleeding control and daily functioning, and a decrease in treatment burden compared with on-demand treatment. Their experiences highlight the significant enhancement in quality of life achieved through the adoption of regular prophylaxis. Overcoming long-standing concerns about product safety allowed them to embrace preventive care and realize its benefits in managing their severe VWD.
SN - 2567-3459
SN - 2512-9465
ER -